Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sets New 1-Year Low at $17.03

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating)’s stock price reached a new 52-week low during trading on Friday . The stock traded as low as $17.03 and last traded at $17.03, with a volume of 24248 shares traded. The stock had previously closed at $17.91.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. UBS Group cut their price target on Zentalis Pharmaceuticals to $52.00 in a research note on Monday, November 21st. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 2nd. Wedbush decreased their price objective on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an “outperform” rating for the company in a report on Monday, November 14th. Finally, Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $52.00 to $46.00 in a research note on Monday, November 14th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $46.56.

Zentalis Pharmaceuticals Stock Down 9.9 %

The business has a 50 day moving average of $21.09 and a 200 day moving average of $22.03. The company has a market capitalization of $959.04 million, a P/E ratio of -3.56 and a beta of 1.87.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last announced its earnings results on Wednesday, March 1st. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.17. On average, research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -4.35 EPS for the current year.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,624 shares of the firm’s stock in a transaction on Monday, February 13th. The stock was sold at an average price of $20.42, for a total value of $53,582.08. Following the transaction, the chief financial officer now owns 397,275 shares in the company, valued at approximately $8,112,355.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Melissa B. Epperly sold 2,624 shares of the firm’s stock in a transaction on Monday, February 13th. The stock was sold at an average price of $20.42, for a total transaction of $53,582.08. Following the completion of the transaction, the chief financial officer now directly owns 397,275 shares in the company, valued at $8,112,355.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, President Cam Gallagher sold 3,332 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Monday, February 13th. The shares were sold at an average price of $20.42, for a total transaction of $68,039.44. Following the completion of the transaction, the president now owns 499,771 shares of the company’s stock, valued at approximately $10,205,323.82. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,763 shares of company stock valued at $873,760. 19.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC grew its stake in shares of Zentalis Pharmaceuticals by 3,284.6% during the 3rd quarter. Barclays PLC now owns 116,598 shares of the company’s stock worth $2,526,000 after purchasing an additional 113,153 shares during the period. Virtus ETF Advisers LLC increased its stake in Zentalis Pharmaceuticals by 120.7% in the second quarter. Virtus ETF Advisers LLC now owns 4,786 shares of the company’s stock valued at $134,000 after purchasing an additional 2,617 shares during the last quarter. Sofinnova Investments Inc. boosted its holdings in shares of Zentalis Pharmaceuticals by 77.6% in the 3rd quarter. Sofinnova Investments Inc. now owns 583,357 shares of the company’s stock valued at $12,636,000 after purchasing an additional 254,960 shares during the last quarter. Eventide Asset Management LLC lifted its stake in shares of Zentalis Pharmaceuticals by 85.4% in the 3rd quarter. Eventide Asset Management LLC now owns 1,861,000 shares of the company’s stock valued at $40,309,000 after purchasing an additional 857,000 shares in the last quarter. Finally, Ensign Peak Advisors Inc boosted its position in Zentalis Pharmaceuticals by 81.8% during the 3rd quarter. Ensign Peak Advisors Inc now owns 151,853 shares of the company’s stock worth $3,289,000 after purchasing an additional 68,327 shares during the period.

About Zentalis Pharmaceuticals

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.